The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

GW Pharmaceuticals PLC

Nasdaq: GWPH
Last

(U.S.) $106.13

Today's change-1.89 -1.75%
Updated May 26 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

GW Pharmaceuticals PLC

Nasdaq: GWPH
Last

(U.S.) $106.13

Today's change-1.89 -1.75%
Updated May 26 4:00 PM -4GMT. Delayed by at least 15 minutes.

GW Pharmaceuticals PLC down (U.S.)$1.89

GW Pharmaceuticals PLC closed sharply lower Friday, dropping (U.S.)$1.89 or 1.75% to (U.S.)$106.13. Although unchanged over the last five days, shares are down 5.03% for the last year to date. This security has outperformed the S&P 500 by 2.12% during the last year.

Key company metrics

  • Open(U.S.) $107.97
  • Previous close(U.S.) $108.02
  • High(U.S.) $108.16
  • Low(U.S.) $105.82
  • Bid / Ask(U.S.) $98.12 / (U.S.) $120.77
  • YTD % change-5.03%
  • Volume219,092
  • Average volume (10-day)253,345
  • Average volume (1-month)274,918
  • Average volume (3-month)311,711
  • 52-week range(U.S.) $79.62 to (U.S.) $137.88
  • Beta2.69
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEG0.38×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$4.12
Updated May 26 4:00 PM -4GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-1,029.50%

Although this company's net profit margin is negative, it is above the industry average and implies that GW Pharmaceuticals PLC is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.04%Sector:Industry:

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2017Q1/2017Q4/2016Q3/2016
Fiscal Quarter Endvalues in $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue2222
Total other revenue--------
Total revenue2222
Gross profit1112
Total cost of revenue1111
Total operating expense41202621
Selling / general / administrative9776
Research & development27252426
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-39-18-25-18
Interest income (expense), net non-operating0000
Gain (loss) on sale of assets--------
Other--------
Income before tax-39-18-24-18
Income after tax-34-16-17-12
Income tax, total-5-3-8-6
Net income-34-16-17-12
Total adjustments to net income--------
Net income before extra. items-34-16-17-12
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-34-16-17-12
Inc. avail. to common incl. extra. items-34-16-17-12
Diluted net income-34-16-17-12
Dilution adjustment0------
Diluted weighted average shares304303295263
Diluted EPS excluding extraordinary itemsvalue per share-0.11-0.05-0.06-0.05
Dividends per sharevalue per share----0.000.00
Diluted normalized EPSvalue per share-0.11-0.05-0.06-0.05